Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
-
MORRISVILLE, N.C., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Wednesday, November 14, at...
-
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
-
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
-
External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidatesExtension of...
-
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
-
Trial enrollment completed meaningfully ahead of scheduleTop line results targeted to be communicated no later than mid-NovemberFavorable and consistent safety profile of SB206 enabled escalation to...
-
Written minutes received from Type C meeting with FDAModerate-to-severe patient pathway re-affirmedAdditional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24,...
-
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
-
Company provides a comprehensive business update via its second quarter 2018 Form 10-Q filingNew incentive plan is aligned with the achievement of two specific stockholder value targets and is...